By Chris Wack
Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering.
Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the session, and are down 33% in the past 12 months.
The company said the financing is expected to fund it through the anticipated data readout for the Phase 3 trial for casdatifan, its potential treatment for clear cell renal cell carcinoma.
Arcus also said that Gilead's time-limited exclusive option rights to casdatifan have expired, allowing it to retain ownership of the drug.
Morgan Stanley cut its price target for Arcus stock to $25 share, from $36 a share, while maintaining its Overweight rating.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 18, 2025 13:23 ET (18:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.